Bunnage Mark E.
- SEC CIK
- 0002100735
In the past year, 4 open-market sale filings worth $3.00M and no purchases.
Current role at each company
- VRTX Vertex Pharmaceuticals IncEVP, Chief Scientific Officeras of May 19, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $3.00M
- 4 filings
- Net
- −$3.00M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Bunnage Mark E. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 19, 2026 (view filing) | May 15 | 4 days | Bunnage Mark E.EVP, Chief Scientific Officer | SSale | −33 | $453.45 | −$15.0K | −0.5%7.28K after | 10b5-1 |
| Feb 26, 2026 (view filing) | Feb 25 | 1 day | Bunnage Mark E.EVP, Chief Scientific Officer | SSale | −620 | $486.35 | −$301.5K | −7.8%7.28K after | 10b5-1 |
| Feb 19, 2026 (view filing) | Feb 17-18 | 2 days | Bunnage Mark E.EVP, Chief Scientific Officer | SSale | −3.62K | $484.31 | −$1.75M | −29.9%8.49K after | 2 lots10b5-1 |
| Feb 12, 2026 (view filing) | Feb 11 | 1 day | Bunnage Mark E.EVP, Chief Scientific Officer | SSale | −2.02K | $460.43 | −$930.5K | −13.5%12.9K after | 10b5-1 |